Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI (Computerized Thermal Imaging) gets FDA panel review date for thermal imager:

This article was originally published in Clinica

Executive Summary

The US FDA's radiological devices panel is scheduled to review on October 16 Computerized Thermal Imaging's (CTI) premarket approval application for its thermal breast imaging system. The BCS 2100 system, which is being assessed by the panel as an adjunct to mammography, uses thermal imaging technology to provide a physiological profile of the breast, rather than the anatomical profile provided by mammograms. The device could provide an accurate and non-invasive way of helping to distinguish between benign and malignant lesions, thereby preventing unnecessary surgical breast biopsies, says the Lake Oswego, Oregon firm, which already has approval to market the system in Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel